Gsk (GSK) Depreciation & Amortization (CF) (2009 - 2017)

Gsk (GSK) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $1.3 billion in Q4 2017.

• For the quarter ending Q4 2017, Depreciation & Amortization (CF) rose 7.88% year-over-year to $1.3 billion; the trailing twelve-month figure through Dec 2017 stood at $5.1 billion (up 2.54% YoY), and the FY2023 full-year result was $1.3 billion, up 2.49% from the prior year.
• Depreciation & Amortization (CF) was $1.3 billion for Q4 2017 at Gsk, up from $1.2 billion in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.4 billion in Q4 2015 to a low of $1.2 billion in Q4 2013.
• A 5-year average of $1.3 billion and a median of $1.2 billion in 2014 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) decreased 15.27% in 2013 and gained 9.53% in 2015, its largest moves.
• Gsk's Depreciation & Amortization (CF) stood at $1.2 billion in 2013, then rose by 4.28% to $1.2 billion in 2014, then grew by 9.53% to $1.4 billion in 2015, then retreated by 10.18% to $1.2 billion in 2016, then grew by 7.88% to $1.3 billion in 2017.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $1.3 billion in Q4 2017, $1.2 billion in Q4 2016, and $1.4 billion in Q4 2015.